A detailed history of Nordea Investment Management Ab transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Nordea Investment Management Ab holds 58,572 shares of LGND stock, worth $6.95 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
58,572
Previous 55,602 5.34%
Holding current value
$6.95 Million
Previous $5.57 Million 12.68%
% of portfolio
0.01%
Previous 0.01%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 06, 2025

BUY
$99.95 - $129.9 $296,851 - $385,803
2,970 Added 5.34%
58,572 $6.28 Million
Q3 2024

Nov 05, 2024

SELL
$82.7 - $110.11 $256,121 - $341,010
-3,097 Reduced 5.28%
55,602 $5.57 Million
Q2 2024

Aug 08, 2024

SELL
$68.53 - $87.91 $659,875 - $846,485
-9,629 Reduced 14.09%
58,699 $4.95 Million
Q1 2024

May 02, 2024

SELL
$68.64 - $89.2 $44,135 - $57,355
-643 Reduced 0.93%
68,328 $4.99 Million
Q4 2023

Jan 10, 2024

SELL
$49.57 - $72.63 $118,026 - $172,932
-2,381 Reduced 3.34%
68,971 $4.93 Million
Q3 2023

Nov 13, 2023

SELL
$58.86 - $72.67 $46,852 - $57,845
-796 Reduced 1.1%
71,352 $4.28 Million
Q2 2023

Jul 07, 2023

BUY
$69.53 - $79.33 $35,112 - $40,061
505 Added 0.7%
72,148 $5.2 Million
Q1 2023

Apr 19, 2023

SELL
$65.67 - $77.08 $146,444 - $171,888
-2,230 Reduced 3.02%
71,643 $5.27 Million
Q4 2022

Feb 08, 2023

BUY
$61.72 - $96.74 $242,744 - $380,478
3,933 Added 5.62%
73,873 $4.93 Million
Q3 2022

Oct 19, 2022

SELL
$0.01 - $107.56 $2 - $25,276
-235 Reduced 0.33%
69,940 $6.1 Million
Q2 2022

Aug 09, 2022

SELL
$74.52 - $117.06 $161,559 - $253,786
-2,168 Reduced 3.0%
70,175 $6.09 Million
Q1 2022

Apr 11, 2022

BUY
$94.99 - $151.56 $86,155 - $137,464
907 Added 1.27%
72,343 $8.46 Million
Q4 2021

Jan 20, 2022

SELL
$127.69 - $165.85 $67,803 - $88,066
-531 Reduced 0.74%
71,436 $11.2 Million
Q3 2021

Nov 01, 2021

SELL
$102.33 - $144.73 $7.36 Million - $10.4 Million
-71,967 Reduced 50.0%
71,967 $10.1 Million
Q3 2021

Nov 01, 2021

BUY
$102.33 - $144.73 $7.25 Million - $10.3 Million
70,870 Added 97.0%
143,934 $20.1 Million
Q2 2021

Jul 16, 2021

BUY
$113.03 - $155.64 $921,872 - $1.27 Million
8,156 Added 12.57%
73,064 $9.59 Million
Q1 2021

May 17, 2021

SELL
$99.52 - $215.83 $126,489 - $274,319
-1,271 Reduced 1.92%
64,908 $9.96 Million
Q4 2020

Feb 12, 2021

BUY
$80.55 - $106.05 $1.98 Million - $2.61 Million
24,643 Added 59.33%
66,179 $6.58 Million
Q3 2020

Nov 09, 2020

SELL
$89.56 - $126.72 $3.67 Million - $5.19 Million
-40,994 Reduced 49.67%
41,536 $4.07 Million
Q2 2020

Aug 13, 2020

BUY
$68.28 - $123.65 $2.83 Million - $5.13 Million
41,449 Added 100.9%
82,530 $9.23 Million
Q1 2020

May 15, 2020

BUY
$63.37 - $107.88 $105,320 - $179,296
1,662 Added 4.22%
41,081 $3.03 Million
Q4 2019

Feb 11, 2020

BUY
$96.94 - $113.59 $100,526 - $117,792
1,037 Added 2.7%
39,419 $4.14 Million
Q3 2019

Nov 13, 2019

BUY
$86.25 - $120.16 $1.09 Million - $1.52 Million
12,645 Added 49.13%
38,382 $3.84 Million
Q2 2019

Aug 14, 2019

BUY
$107.38 - $129.34 $857,966 - $1.03 Million
7,990 Added 45.02%
25,737 $2.94 Million
Q1 2019

May 20, 2019

SELL
$105.93 - $142.47 $83,684 - $112,551
-790 Reduced 4.26%
17,747 $2.23 Million
Q4 2018

Feb 14, 2019

SELL
$128.36 - $272.13 $8,215 - $17,416
-64 Reduced 0.34%
18,537 $2.52 Million
Q3 2018

Nov 14, 2018

BUY
$211.18 - $274.49 $557,092 - $724,104
2,638 Added 16.53%
18,601 $5.11 Million
Q2 2018

Aug 13, 2018

SELL
$150.77 - $207.98 $604,135 - $833,375
-4,007 Reduced 20.07%
15,963 $3.31 Million
Q1 2018

May 14, 2018

BUY
$138.63 - $182.62 $238,304 - $313,923
1,719 Added 9.42%
19,970 $3.3 Million
Q4 2017

Feb 12, 2018

BUY
$128.36 - $147.04 $128,616 - $147,334
1,002 Added 5.81%
18,251 $2.5 Million
Q3 2017

Nov 09, 2017

BUY
$120.91 - $137.94 $2.09 Million - $2.38 Million
17,249
17,249 $2.35 Million

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $2B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Nordea Investment Management Ab Portfolio

Follow Nordea Investment Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nordea Investment Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Nordea Investment Management Ab with notifications on news.